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Copyright © 200? JCBN Summary Cellobiose is produced from cellulose using specific bacterial enzymes, and is
hydrolyzed into glucose by the enzymes cellobiosidase and cellulase. In this study, we examined
the effects of cellobiose on colonic mucosal damage in a dextran sulfate sodium (DSS) colitis
model. BALB/c mice were divided into two groups. In the first group, the mice were fed 3.5%
DSS mixed with normal chow. In the second group, the mice were fed 3.5% DSS plus 6.0 or
9.0% (weight/weight) cellobiose mixed with normal chow. The development of colitis was
assessed on day 21. Mucosal cytokine expression was analyzed by RT-PCR. Body weight loss
was significantly attenuated in the 9.0% cellobiose-fed DSS mice as compared to the DSS mice.
Colonic weight/length ratio, a maker of tissue edema, was significantly higher in the DSS mice
than in the 9.0% cellobiose-fed DSS mice. The disease activity index and histological colitis
score were also significantly higher in the DSS mice than in the 9.0% cellobiose-fed DSS mice.
Mucosal mRNA expression for IL-1β, TNF-α, IL-17 and IP-10 were markedly reduced in the
9.0% cellobiose-fed DSS mice. In conclusion, a preventive effect of cellobiose against DSS
colitis suggests its clinical use for inflammatory bowel diseases patients.
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Introduction
Inflammatory bowel diseases (IBD), ulcerative colitis
(UC) and Crohn’s disease (CD) are chronic intestinal dis-
orders of unknown etiology. As a characteristic feature of
IBD, the mucosal immune system shows an aberrant
response towards luminal antigens such as commensal
bacteria in genetically susceptible individuals [1, 2]. The
correlation between a dysregulated bacterial ecosystem
and mucosal inflammation has been reported in a variety of
clinical and basic literature ion IBD [3–5].
It is well known that non-absorbable and/or non-digestible
oligosaccharides escape digestion in the upper gastro-
intestinal tract, and when transferred to the colon, they are
fermented by commensal bacteria, catabolized to short chain
fatty acids and hydrogen, methane and carbon dioxide [6, 7].
Short-chain fatty acids (SCFAs) are important nutrients for
epithelial cells, and among the SCFAs, butyrate most
effectively protects against intestinal mucosal injury and
promotes mucosal healing.
Cellobiose (o-β-D-glucopyranosyl-(1→4)-α-D-glucopy-
ranose) is produced from cellulose using specific bacterial
enzymes, and is hydrolyzed into two molecules of glucose
by the enzymes cellobiosidase and cellulase [6]. However,
the physiological functions of cellobiose are not well under-
stood due to its difficulty in mass production. Recently, it
has been developed from the viewpoint of biomass utiliza-
tion, and cellobiose is now available for food and feed [6]. In
this study, we examined the effects of cellobiose on colonic
mucosal damage and on the intestinal environment in a
dextran sulfate sodium (DSS) colitis model.T. Nishimura et al.
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Materials and Methods
Induction of colitis
Six- to eight-week-old male BALB/c mice were purchased
from Charles River Japan (Kanagawa, Japan). They were
acclimatized for one week before the experiment, and were
housed individually in a room maintained at 22°C under a
12-h day/night cycle throughout the experiments. According
to previous reports describing preventive effects of pre-
biotics on DSS-colitis [8,  9], we used mild DSS-colitis
model. The mice were divided into two groups. In the first
group, the mice were fed 3.5% [weight/weight (wt/wt)] DSS
(molecular weight 5000; Wako Pure Chemical Industries,
Ltd, Osaka, Japan) mixed with normal chow (MF; Oriental
Yeast Co., Ltd, Tokyo, Japan) and water ad libitum. In the
second group, mice were fed 3.5% DSS plus 6.0 or 9.0%
(wt/wt) cellobiose (Nippon Paper Chemicals Co., LTD,
Tokyo, Japan) mixed with normal chow. This study protocol
was approved by the Animal Care and Use Committee of the
Shiga University of Medical Science (Otsu, Japan).
Assessment of inflammation in DSS-induced colitis
A daily clinical assessment of the DSS-induced colitis
was performed, including a measurement of food intake and
body weight, an evaluation of stool consistency, and the
presence of blood in the stools by the guaiac paper test. The
stool consistency was assessed using the following four
point-scale: 0, normal; 1, soft; 2, very soft but formed; and 3,
liquid. The intensity of the guaiac paper test was scored by
the following scale: 0, negative; 1, faintly blue; 2, moder-
ately blue; 3, dark blue; and 4, blood visible. A validated
clinical disease activity index ranging from 0 to 4 was
calculated using the following parameters: stool consistency,
presence of fecal blood, and changes in body weight [10].
The mice were sacrificed on day 14, and the length and
weight of the colon were measured.
Histology
A histological examination was performed on three
samples of the distal colon from each animal. The samples
were fixed in 10% buffered formalin, dehydrated in ethanol,
and then embedded in paraffin. Four micron-thick sections
were then prepared and stained with hematoxylin and eosin.
All histologic evaluations were performed in a blinded
fashion using a validated scoring system [11].
Reverse transcription-polymerase chain reaction (RT-PCR)
Cytokine mRNA expression in the mucosa was evaluated
by RT-PCR. Total cellular RNA was isolated by the acid
guanidium thiocyanate-phenol-chloroform (AGPC) method
[12]. For each sample, the first-strand cDNA was synthe-
sized using 0.5 μg of total cellular RNA with an oligo(dT)
primer and Superscript reverse transcriptase (GIBCO BRL,
Rockville, MD). One μl of the cDNA sample was amplified
in 25 μl of a reaction mixture containing 10 × Taq Buffer
(Perkin Elmer Cetus Corp., Norwalk, CT), 1.5 mM MgCl2,
0.1 μM of each 5' and 3' primers, and 1 U of TaqGold
polymerase (Perkin-Elmer Cetus) (Table 1). The PCR was
performed in a thermal cycler (GeneAmp Model 2400;
Perkin-Elmer Cetus) for 25 cycles (94°C for 30 s, 55°C
for 30 s and 72°C for 40 s), followed by an 8 min. extension
at 72°C. Five μl of the PCR products were subjected to
electrophoresis on 1.5% agarose gels, and were stained
with 0.5 μg/mL ethidium bromide. A 100-bp DNA ladder
(GIBCO BRL) was used as the marker. Primers specific for
the mouse cytokines have been described in previous reports
[13, 14].
Statistical analysis
Statistical analysis were performed using one-way
ANOVA with Scheffe’s post hoc test or the Kruskal-Wallis
test when appropriate. A two-way ANOVA for repeated
measures was used to test for group and time effects on the
clinical data (e.g., disease activity index). *p values less
than 0.05 were considered to be statistically significant.
Table 1. PCR primers used in this study
Genes Sequence PCR products (bp)
IL-1β F 5'-CAG GAT GAG GAC ATG AGC ACC-3' 983
R 5'-CTC TGC AGA CTC AAA CTC CAC-3'
TNF-α F 5'-ATG AGC ACA GAA AGC ATG ATC-3' 306
R 5'-TAC AGG CTT GTC ACT CGA ATT-3'
IL-17 F 5'-TCT CAT CCA GCA AGA GAT CC-3' 249
R 5'-AGT TTG GGA CCC CTT TAC AC-3'
IP-10 F 5'-GTG CTG CCG TCA TTT TCT GC-3' 230
R 5'-CTT AGA TTC CGG ATT CAG AC-3'
β-actin F 5'-GTG GGC CGC TCT AGG CAC CA-3' 245
R 5'-CGG TTG GCC TTA GGG TTC AGG GG-3Cellobiose and Colitis
Vol. 46, No. 2, 2010
107
Results
As shown in Fig. 1, at day 15 after the initiation of
DSS-induced colitis, the body weight was significantly
lower in the DSS-treated mice than in the DSS plus 9%
cellobiose-treated mice. The colonic weight/length ratio, a
maker of tissue edema, was significantly higher in the DSS-
treated mice than in the DSS plus cellobiose-treated mice
(*p<0.05, Fig. 2). On day 21, the disease activity index
was significantly higher in the DSS-treated mice than in the
DSS plus cellobiose-treated mice (*p<0.05, Fig. 2). These
observations indicate that cellobiose suppressed the develop-
ment of DSS colitis.
DSS-colitis is characterized by histological findings such
as edema, the infiltration of inflammatory cells into both the
mucosa and submucosa, the destruction of epithelial cells
and mucosal thickening. The histological score was signifi-
cantly higher in the DSS-treated mice than in the DSS plus
curcumin-treated mice (*p<0.05, Fig. 2). As shown in
Fig. 3, the histological analysis indicated that the histo-
logical severity of the colitis was more severe in the DSS-
treated mice as compared to the DSS plus cellobiose-treated
mice.
Mucosal cytokine mRNA expression was evaluated by
semi-quantitative RT-PCR, and a representative picture is
shown in Fig. 4. The DSS mice showed an increased expres-
sion of IL-1β, TNF-α, IL-17 and IP-10. Treatment with
cellobiose markedly reduced the expression of these cyto-
kine mRNAs. Similar results were observed in 5 different
experiments.
Discussion
Although the detailed pathogenesis of IBD is not known,
our understanding of the cellular and molecular mechanisms
associated with IBD has increased dramatically. Several
drugss (corticosteroids, 5-aminosalicylate compounds and
immune suppressing agents) and new therapeutics (e.g.
leukocytapheresis and anti-TNF-α antibody) have proven
effective for the treatment of IBD. These treatments were
based on the attenuation of local inflammation in the
mucosa.
It has been recently reported that an improvement or
reinforcement in colonic mucosal barrier functions via
modifying the luminal environment may play an important
Fig. 1. Changes in body weight. The mice were fed 3.5% DSS,
3.5% DSS plus 6.0% cellobiose (wt/wt) or 3.5% DSS
plus 9.0% cellobiose (Nippon Paper Chemicals Co.,
LTD, Tokyo, Japan). The weight of each individual
mouse was then followed daily. The data represent
means +/− SEM (n = 5 mice/group). *p<0.05: DSS plus
9.0% cellobiose group versus DSS group.
Fig. 2. Effects of cellobiose on the colonic weight/length, disease activity index (B), and histological score (C) on day 21. The scoring
criteria were described in the Materials and Methods. The data represent means +/− SEM (n = 5 mice/group). *p<0.05.T. Nishimura et al.
J. Clin. Biochem. Nutr.
108
role in the treatment of UC. One of these therapeutic
strategies is prebiotics, which escape digestion in the upper
intestinal tract and are utilized as substrates for the micro-
flora. It is generally accepted that prebiotics induce the
production of short chain fatty acids (SCFAs), such as
acetate, propionate and butyrate, as the major byproduct
nutrients for epithelial cells by the intestinal flora [15–18].
The typical concentration of each SCFA is ~10 mM [19]. Of
the most abundant SCFAs, butyrate has been shown to have
significant protective effects on the colonic epithelium both
in vivo and in vitro. Butyrate serves as the primary energy
source for the normal colonic epithelium [17], and stimu-
lates the growth of the colonic mucosa [17]. However, in
tumor cell lines, it inhibits growth and induces apoptosis
[20]. Previously, the effectiveness for butyrate enemas in the
treatment of active ulcerative colitis (UC) has been reported
[21, 22]. The precise molecular mechanisms underlying this
response have not been identified, but it is believed to be
partially based on the inhibitory actions of butyrate on the
production of pro-inflammatory mediators in the intestine.
For example, butyrate inhibits both IL-8 and complement
components from colonic epithelial cells [23], and blocks
IP-10 secretion from colonic myofibroblasts [24].
Cellulose is the main component of the lignocellulosic
biomass. It is preferable to use the lignocellulosic biomass
instead of edible sugar, because it is cheap and exists
abundantly on Earth. Cellobiose is one of the main compo-
nents of oligosaccharides derived from cellulose, and recent
studies suggest that cellobiose, fermented by the intestinal
microflora, acts as a prebiotic [16–18]. Dextran sulfate
sodium (DSS)-induced colitis is commonly used to evaluate
the efficacy of new drugs for inflammatory bowel disease.
Oral cellobiose administration improved both clinical and
pathological signs of colitis with a decrease in mucosal
proinflammatory cytokines mRNA expression. Previous
studies have shown that cytokines evaluated in this study
play important roles in the pathogenesis of experimental
colitis and human IBD [25–27]. So, it was speculated that
Fig. 3. Histological analyses for cellobiose effects on DSS-colitis. The colons were excised at 21 days after DSS treatment, and stained
with hematoxylin and eosin (HE). Magnification ×100.Cellobiose and Colitis
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cellobiose acts at least in part through the inhibition of pro-
inflammatory cytokine expression via the anti-inflammatory
actions of SCFAs, especially butyrate. To clarify how cello-
biose modulates intestinal inflammation, alterations in the
microbiota and fecal concentrations of SCFAs should be
investigated in cellobiose-treated mice.
In conclusion, a protective effect of cellobiose against
DSS colitis suggests its clinical use for IBD patients.
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